

# Fabiola Atzeni

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6858965/fabiola-atzeni-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

203  
papers

4,981  
citations

37  
h-index

63  
g-index

228  
ext. papers

6,125  
ext. citations

5.5  
avg, IF

5.71  
L-index

#	Paper	IF	Citations
203	EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome.. <i>Annals of the Rheumatic Diseases</i> , <b>2022</b> ,	2.4	6
202	Safety of JAK inhibitors: focus on cardiovascular and thromboembolic events.. <i>Expert Review of Clinical Immunology</i> , <b>2022</b> ,	5.1	2
201	Rheumatoid Arthritis disease activity assessment in routine care: performance of the most widely used composite disease activity indices and patient-reported outcome measures. <i>Acta Biomedica</i> , <b>2021</b> , 92, e2021238	3.2	0
200	Impact of smoking habit on adult-onset Still's disease prognosis, findings from a multicentre observational study. <i>Clinical Rheumatology</i> , <b>2021</b> , 1	3.9	1
199	Comparison of Efficacy of Ketoprofen and Ibuprofen in Treating Pain in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. <i>Pain and Therapy</i> , <b>2021</b> , 10, 577-588	3.6	8
198	Cross Cultural Adaptation and Validation of Italian Version of the Leeds Assessment of Neuropathic Symptoms and Signs Scale and Pain DETECT Questionnaire for the Distinction between Nociceptive and Neuropathic Pain. <i>Pain Research and Management</i> , <b>2021</b> , 2021, 6623651	2.6	5
197	Cardiovascular effects of approved drugs for rheumatoid arthritis. <i>Nature Reviews Rheumatology</i> , <b>2021</b> , 17, 270-290	8.1	12
196	Risk of coronavirus disease 2019 hospitalization and mortality in rheumatic patients treated with hydroxychloroquine or other conventional disease-modifying anti-rheumatic drugs in Italy. <i>Rheumatology</i> , <b>2021</b> , 60, SI25-SI36	3.9	5
195	Anti-IL-17 Agents in the Treatment of Axial Spondyloarthritis. <i>ImmunoTargets and Therapy</i> , <b>2021</b> , 10, 141-153	9	3
194	Behçet disease: From pathogenesis to novel therapeutic options. <i>Pharmacological Research</i> , <b>2021</b> , 167, 105593	10.2	4
193	Cannabis and Autoimmunity: Possible Mechanisms of Action. <i>ImmunoTargets and Therapy</i> , <b>2021</b> , 10, 261-271	3.71	5
192	Safety and effectiveness of biosimilar of Rituximab CT-P10 in the treatment of cryoglobulinemic vasculitis: the MARBLE study (Mixed cryoglobulinemia Rituximab Biosimilar). <i>Internal and Emergency Medicine</i> , <b>2021</b> , 16, 149-156	3.7	7
191	Definition of fibromyalgia severity: findings from a cross-sectional survey of 2339 Italian patients. <i>Rheumatology</i> , <b>2021</b> , 60, 728-736	3.9	4
190	Differences in depression, anxiety and stress disorders between fibromyalgia associated with rheumatoid arthritis and primary fibromyalgia. <i>Stress and Health</i> , <b>2021</b> , 37, 255-262	3.7	0
189	The effect of drugs used in rheumatology for treating SARS-CoV2 infection. <i>Expert Opinion on Biological Therapy</i> , <b>2021</b> , 21, 219-228	5.4	3
188	The association between body mass index and fibromyalgia severity: data from a cross-sectional survey of 2339 patients. <i>Rheumatology Advances in Practice</i> , <b>2021</b> , 5, rkab015	1.1	0
187	Dissecting the clinical heterogeneity of adult-onset Still's disease: results from a multi-dimensional characterization and stratification. <i>Rheumatology</i> , <b>2021</b> , 60, 4844-4849	3.9	7

186	Is central sensitization an important determinant of functional disability in patients with chronic inflammatory arthritides?. <i>Therapeutic Advances in Musculoskeletal Disease</i> , <b>2021</b> , 13, 1759720X21993252	3.8	5
185	Diffuse Idiopathic Skeletal Hyperostosis (DISH) and a Possible Inflammatory Component. <i>Current Rheumatology Reports</i> , <b>2021</b> , 23, 6	4.9	10
184	The Rheumatology Drugs for COVID-19 Management: Which and When?. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	8
183	The Key Comorbidities in Patients with Rheumatoid Arthritis: A Narrative Review. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	12
182	Pain in Women: A Perspective Review on a Relevant Clinical Issue that Deserves Prioritization. <i>Pain and Therapy</i> , <b>2021</b> , 10, 287-314	3.6	9
181	Psoriatic Arthritis and Metabolic Syndrome: Is There a Role for Disease Modifying Anti-Rheumatic Drugs?. <i>Frontiers in Medicine</i> , <b>2021</b> , 8, 735150	4.9	1
180	Antifibrotic drugs in connective tissue disease-related interstitial lung disease (CTD-ILD): from mechanistic insights to therapeutic applications. <i>Drugs in Context</i> , <b>2021</b> , 10,	5.2	1
179	The effect of novel coronavirus disease-2019 (COVID-19) on fibromyalgia syndrome. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39 Suppl 130, 72-77	2.2	3
178	Occurrence and predictive factors of high blood pressure, type 2 diabetes, and metabolic syndrome in rheumatoid arthritis: findings from a 3-year, multicentre, prospective, observational study. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39, 995-1002	2.2	0
177	Metabolic Syndrome in Systemic Sclerosis Patients: Data from Clinical Practice. <i>Israel Medical Association Journal</i> , <b>2021</b> , 23, 262-263	0.9	
176	Fibromyalgia position paper. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39 Suppl 130, 186-193	2.2	1
175	One year in review 2021: fibromyalgia. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39 Suppl 130, 3-12	2.2	1
174	Efficacy and Safety of Biosimilar and Originator Etanercept in Rheumatoid Arthritis Patients: Real-Life Data. <i>Israel Medical Association Journal</i> , <b>2021</b> , 23, 344-349	0.9	
173	Diagnostic and therapeutic care pathway for fibromyalgia. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39 Suppl 130, 120-127	2.2	
172	One year in review 2021: fibromyalgia. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39, 3-12	2.2	3
171	Diagnostic and therapeutic care pathway for fibromyalgia. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39, 120-127	2.2	0
170	Influence of the age at diagnosis in the disease expression of primary Sjögren syndrome. Analysis of 12,753 patients from the Sjögren Big Data Consortium. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39, 166-174	2.2	0
169	Fibromyalgia position paper. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39, 186-193	2.2	5

168	Influence of the age at diagnosis in the disease expression of primary Sjögren syndrome. Analysis of 12,753 patients from the Sjögren Big Data Consortium.. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39 Suppl 133, 166-174	2.2	
167	The contribution of HERV-E clone 4-1 and other HERV-E members to the pathogenesis of rheumatic autoimmune diseases. <i>Apmis</i> , <b>2020</b> , 128, 367-377	3.4	5
166	How to handle patients with autoimmune rheumatic and inflammatory bowel diseases in the COVID-19 era: An expert opinion. <i>Autoimmunity Reviews</i> , <b>2020</b> , 19, 102574	13.6	29
165	Study of entheses in patients with spondyloarthritis and inflammatory bowel disease with and without fibromyalgia: The importance of ultrasonography. <i>Joint Bone Spine</i> , <b>2020</b> , 87, 507-508	2.9	0
164	The Neuropathic Pain Features in Psoriatic Arthritis: A Cross-sectional Evaluation of Prevalence and Associated Factors. <i>Journal of Rheumatology</i> , <b>2020</b> , 47, 1198-1203	4.1	8
163	Concerns about the safety of anti-TNF agents when treating rheumatic diseases. <i>Expert Opinion on Drug Safety</i> , <b>2020</b> , 19, 695-705	4.1	8
162	Toxicological considerations in the treatment of axial spondylo-arthritis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2020</b> , 16, 663-672	5.5	1
161	Parenchymal lung disease in adult onset Still's disease: an emergent marker of disease severity-characterisation and predictive factors from Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort of patients. <i>Arthritis Research and Therapy</i> , <b>2020</b> , 22, 151	5.7	13
160	Therapeutic peptides for the treatment of systemic lupus erythematosus: a place in therapy. <i>Expert Opinion on Investigational Drugs</i> , <b>2020</b> , 29, 845-867	5.9	1
159	Potential Role of Anti-interleukin (IL)-6 Drugs in the Treatment of COVID-19: Rationale, Clinical Evidence and Risks. <i>BioDrugs</i> , <b>2020</b> , 34, 415-422	7.9	39
158	Diagnosis of fibromyalgia: comparison of the 2011/2016 ACR and AAPT criteria and validation of the modified Fibromyalgia Assessment Status. <i>Rheumatology</i> , <b>2020</b> , 59, 3042-3049	3.9	17
157	Ferritin and C-reactive protein are predictive biomarkers of mortality and macrophage activation syndrome in adult onset Still's disease. Analysis of the multicentre Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort. <i>PLoS ONE</i> , <b>2020</b> , 15, e0235326	3.7	15
156	Dynamic Contrast-Enhanced MRI Confirms Rapid And Sustained Improvement Of Rheumatoid Arthritis Induced By Tocilizumab Treatment: An Italian Multicentre Study. <i>Biologics: Targets and Therapy</i> , <b>2020</b> , 14, 13-21	4.4	2
155	Safety of Abatacept in Italian Patients with Rheumatoid Arthritis and Interstitial Lung Disease: A Multicenter Retrospective Study. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	23
154	Recurrent intracranial hemorrhage and cerebral venous sinus thrombosis: an atypical case of Neuro-Behçet's Syndrome. <i>Clinical Neurology and Neurosurgery</i> , <b>2020</b> , 191, 105680	2	1
153	Safety Profile of Biologics Used in Rheumatology: An Italian Prospective Pharmacovigilance Study. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	4
152	Cardiovascular Consequences of Autoimmune Rheumatic Diseases. <i>Current Vascular Pharmacology</i> , <b>2020</b> , 18, 566-579	3.3	1
151	Extra-intestinal manifestations of inflammatory bowel diseases. <i>Pharmacological Research</i> , <b>2020</b> , 161, 105206	10.2	6

150	Cancer risk and tumour necrosis factor inhibitors in patients with inflammatory arthritis. <i>Pharmacological Research</i> , <b>2020</b> , 158, 104507	10.2	2
149	Laboratory Monitoring of Biological Therapies in Rheumatology: The Role of Immunogenicity. <i>Annals of Laboratory Medicine</i> , <b>2020</b> , 40, 101-113	3.1	10
148	Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicentre retrospective study. <i>Internal Medicine Journal</i> , <b>2020</b> , 50, 1085-1090	1.6	38
147	Cardiovascular risk in ankylosing spondylitis and the effect of anti-TNF drugs: a narrative review. <i>Expert Opinion on Biological Therapy</i> , <b>2020</b> , 20, 517-524	5.4	10
146	Anti-adalimumab and anti-certolizumab antibodies titers after discontinuation of adalimumab: two case reports. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2020</b> , 58, e105-e108	5.9	2
145	Fibromyalgia: an update on clinical characteristics, aetiopathogenesis and treatment. <i>Nature Reviews Rheumatology</i> , <b>2020</b> , 16, 645-660	8.1	62
144	Differences between diffuse idiopathic skeletal hyperostosis and spondyloarthritis. <i>Immunotherapy</i> , <b>2020</b> , 12, 749-756	3.8	4
143	Comment on: Diagnosis of fibromyalgia: comparison of the 2011/2016 ACR and AAPT criteria and validation of the modified Fibromyalgia Assessment Status: reply. <i>Rheumatology</i> , <b>2020</b> , 59, e81	3.9	1
142	Prescribing motivations and patients' characteristics related to the use of biologic drugs in adult-onset Still's disease: analysis of a multicentre "real-life" cohort. <i>Rheumatology International</i> , <b>2020</b> , 40, 107-113	3.6	10
141	Imaging of diffuse idiopathic skeletal hyperostosis (DISH). <i>RMD Open</i> , <b>2020</b> , 6,	5.9	12
140	Italian recommendations for influenza and pneumococcal vaccination in adult patients with autoimmune rheumatic diseases. <i>Clinical and Experimental Rheumatology</i> , <b>2020</b> , 38, 245-256	2.2	1
139	Assessment of enthesitis in patients with psoriatic arthritis and fibromyalgia using clinical examination and ultrasound. <i>Clinical and Experimental Rheumatology</i> , <b>2020</b> , 38 Suppl 123, 31-39	2.2	7
138	Adding medical cannabis to standard analgesic treatment for fibromyalgia: a prospective observational study. <i>Clinical and Experimental Rheumatology</i> , <b>2020</b> , 38 Suppl 123, 53-59	2.2	6
137	Hyperbaric oxygen therapy in fibromyalgia and the diseases involving the central nervous system. <i>Clinical and Experimental Rheumatology</i> , <b>2020</b> , 38 Suppl 123, 94-98	2.2	3
136	Systemic phenotype related to primary Sjögren's syndrome in 279 patients carrying isolated anti-La/SSB antibodies. <i>Clinical and Experimental Rheumatology</i> , <b>2020</b> , 38 Suppl 126, 85-94	2.2	1
135	Ferritin and C-reactive protein are predictive biomarkers of mortality and macrophage activation syndrome in adult onset Still's disease. Analysis of the multicentre Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCs) cohort <b>2020</b> , 15, e0235326		
134	Ferritin and C-reactive protein are predictive biomarkers of mortality and macrophage activation syndrome in adult onset Still's disease. Analysis of the multicentre Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCs) cohort <b>2020</b> , 15, e0235326		
133	Ferritin and C-reactive protein are predictive biomarkers of mortality and macrophage activation syndrome in adult onset Still's disease. Analysis of the multicentre Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCs) cohort <b>2020</b> , 15, e0235326		

132	Ferritin and C-reactive protein are predictive biomarkers of mortality and macrophage activation syndrome in adult onset Still's disease. Analysis of the multicentre Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCs) cohort <b>2020</b> , 15, e0235326		
131	Subclinical and clinical atherosclerosis in rheumatoid arthritis: results from the 3-year, multicentre, prospective, observational GIRRCs (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) study. <i>Arthritis Research and Therapy</i> , <b>2019</b> , 21, 204	5.7	19
130	Medical cannabis and cannabinoids in rheumatology: where are we now?. <i>Expert Review of Clinical Immunology</i> , <b>2019</b> , 15, 1019-1032	5.1	11
129	Psoriatic arthritis: From pathogenesis to pharmacologic management. <i>Pharmacological Research</i> , <b>2019</b> , 148, 104394	10.2	12
128	IL-6 Involvement in pain, fatigue and mood disorders in rheumatoid arthritis and the effects of IL-6 inhibitor sarilumab. <i>Pharmacological Research</i> , <b>2019</b> , 149, 104402	10.2	23
127	A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. <i>Rheumatology</i> , <b>2019</b> , 58, 1755-1766	3.9	128
126	Malar rash is a predictor of subclinical airway inflammation in patients with systemic lupus erythematosus: a pilot study. <i>Clinical Rheumatology</i> , <b>2019</b> , 38, 2541-2546	3.9	6
125	Severe bitter taste associated with apremilast. <i>Dermatologic Therapy</i> , <b>2019</b> , 32, e12876	2.2	6
124	Systemic rheumatic diseases: From biological agents to small molecules. <i>Autoimmunity Reviews</i> , <b>2019</b> , 18, 583-592	13.6	45
123	Noninvasive imaging methods for evaluating cardiovascular involvement in patients with rheumatoid arthritis before and after anti-TNF drug treatment. <i>Future Science OA</i> , <b>2019</b> , 5, FSO396	2.7	4
122	Failure of anti-TNF treatment in patients with rheumatoid arthritis: The pros and cons of the early use of alternative biological agents. <i>Autoimmunity Reviews</i> , <b>2019</b> , 18, 102398	13.6	32
121	Biosimilars vs originators: Are they the same?. <i>Autoimmunity Reviews</i> , <b>2019</b> , 18, 102404	13.6	3
120	Do DMARDs and biologic agents protect from cardiovascular disease in patients with inflammatory arthropathies?. <i>Autoimmunity Reviews</i> , <b>2019</b> , 18, 102401	13.6	5
119	Retrotransposons shuttling genetic and epigenetic information from the nuclear to the mitochondrial compartment: Do they play a pathogenetic role in scleroderma?. <i>Cytokine and Growth Factor Reviews</i> , <b>2019</b> , 49, 42-58	17.9	1
118	La sindrome fibromialgica: dalla diagnosi alla terapia. <i>L Endocrinologo</i> , <b>2019</b> , 20, 361-369	0	
117	Microbial Agents as Putative Inducers of B Cell Lymphoma in Sjögren's Syndrome through an Impaired Epigenetic Control: The State-of-The-Art. <i>Journal of Immunology Research</i> , <b>2019</b> , 2019, 8567364	4.5	7
116	Evaluation of salivary and plasma microRNA expression in patients with Sjögren's syndrome, and correlations with clinical and ultrasonographic outcomes. <i>Clinical and Experimental Rheumatology</i> , <b>2019</b> , 37 Suppl 118, 70-77	2.2	1
115	One year in review 2019: fibromyalgia. <i>Clinical and Experimental Rheumatology</i> , <b>2019</b> , 37 Suppl 116, 3-10	2.2	9

114	Hyperbaric oxygen treatment of fibromyalgia: a prospective observational clinical study. <i>Clinical and Experimental Rheumatology</i> , <b>2019</b> , 37 Suppl 116, 63-69	2.2	3
113	Neuromuscular efficiency in fibromyalgia is improved by hyperbaric oxygen therapy: looking inside muscles by means of surface electromyography. <i>Clinical and Experimental Rheumatology</i> , <b>2019</b> , 37 Suppl 116, 75-80	2.2	1
112	Rate of serious infections in spondyloarthropathy patients treated with anti-tumour necrosis factor drugs: a survey from the Italian registry GISEA. <i>Clinical and Experimental Rheumatology</i> , <b>2019</b> , 37, 649-655	2.2	9
111	Rationale underlying the measurement of fractional exhaled nitric oxide in systemic sclerosis patients. <i>Clinical and Experimental Rheumatology</i> , <b>2019</b> , 37 Suppl 119, 125-132	2.2	0
110	Systemic manifestations of primary Sjögren's syndrome out of the ESSDAI classification: prevalence and clinical relevance in a large international, multi-ethnic cohort of patients. <i>Clinical and Experimental Rheumatology</i> , <b>2019</b> , 37 Suppl 118, 97-106	2.2	4
109	Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry. <i>International Journal of Rheumatic Diseases</i> , <b>2018</b> , 21, 422-430	2.3	17
108	Incidence of cancer in patients with spondyloarthritis treated with anti-TNF drugs. <i>Joint Bone Spine</i> , <b>2018</b> , 85, 455-459	2.9	11
107	Adverse events, clinical considerations and management recommendations in rheumatoid arthritis patients treated with JAK inhibitors. <i>Expert Review of Clinical Immunology</i> , <b>2018</b> , 14, 945-956	5.1	10
106	Accelerated subcutaneous nodulosis in patients with rheumatoid arthritis treated with tocilizumab: a case series. <i>Journal of Medical Case Reports</i> , <b>2018</b> , 12, 154	1.2	10
105	Influence of co-morbid fibromyalgia on disease activity measures and response to tumour necrosis factor inhibitors in axial spondyloarthritis: results from a UK national register. <i>Rheumatology</i> , <b>2018</b> , 57, 1982-1990	3.9	15
104	Cardiovascular Imaging Techniques in Systemic Rheumatic Diseases. <i>Frontiers in Medicine</i> , <b>2018</b> , 5, 26	4.9	3
103	From autoinflammation to autoimmunity: old and recent findings. <i>Clinical Rheumatology</i> , <b>2018</b> , 37, 2305-2321	3.9	28
102	Controlled-release pregabalin in the treatment of fibromyalgia. <i>Expert Review of Neurotherapeutics</i> , <b>2018</b> , 18, 617-623	4.3	2
101	A Review of Chronic Musculoskeletal Pain: Central and Peripheral Effects of Diclofenac. <i>Pain and Therapy</i> , <b>2018</b> , 7, 163-177	3.6	18
100	Biological Agents in Rheumatoid Arthritis: A Cross-Link Between Immune Tolerance and Immune Surveillance. <i>Current Rheumatology Reviews</i> , <b>2018</b> , 14, 131-139	1.6	5
99	TNF inhibitors in rheumatoid arthritis and spondyloarthritis: Are they the same?. <i>Autoimmunity Reviews</i> , <b>2018</b> , 17, 24-28	13.6	28
98	Are the ACR 2010 diagnostic criteria for fibromyalgia better than the 1990 criteria?. <i>Autoimmunity Reviews</i> , <b>2018</b> , 17, 33-35	13.6	24
97	Interstitial lung disease in systemic autoimmune rheumatic diseases: a comprehensive review. <i>Expert Review of Clinical Immunology</i> , <b>2018</b> , 14, 69-82	5.1	33

96	Central nervous system involvement in rheumatoid arthritis patients and the potential implications of using biological agents. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2018</b> , 32, 500-510	5.3	23
95	The influence of comorbidities on the efficacy of tumour necrosis factor inhibitors, and the effect of tumour necrosis factor inhibitors on comorbidities in rheumatoid arthritis: report from a National Consensus Conference. <i>Rheumatology</i> , <b>2018</b> , 57, vii11-vii22	3.9	11
94	Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction. <i>Drug Safety</i> , <b>2018</b> , 41, 1013-1022	5.1	25
93	How immunological profile drives clinical phenotype of primary Sjögren's syndrome at diagnosis: analysis of 10,500 patients (Sjögren Big Data Project). <i>Clinical and Experimental Rheumatology</i> , <b>2018</b> , 36 Suppl 112, 102-112	2.2	34
92	Usefulness of six-minute walk test in systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , <b>2018</b> , 36 Suppl 113, 161-167	2.2	5
91	EULAR recommendations for management of fibromyalgia. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, e54	2.4	23
90	Infections in rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , <b>2017</b> , 29, 323-330	5.3	21
89	Disease Severity in Never Smokers, Ex-Smokers, and Current Smokers With Axial Spondyloarthritis: Results From the Scotland Registry for Ankylosing Spondylitis. <i>Arthritis Care and Research</i> , <b>2017</b> , 69, 1407-1413 <sup>18</sup>	4.7	18
88	Co-Occurrence and Characteristics of Patients With Axial Spondyloarthritis Who Meet Criteria for Fibromyalgia: Results From a UK National Register. <i>Arthritis and Rheumatology</i> , <b>2017</b> , 69, 2144-2150	9.5	44
87	Italian consensus Guidelines for the management of hepatitis B virus infections in patients with rheumatoid arthritis. <i>Joint Bone Spine</i> , <b>2017</b> , 84, 525-530	2.9	12
86	Diffuse idiopathic skeletal hyperostosis (DISH): where we are now and where to go next. <i>RMD Open</i> , <b>2017</b> , 3, e000472	5.9	53
85	Rheumatic diseases and autoimmune vascular dementia. <i>Autoimmunity Reviews</i> , <b>2017</b> , 16, 1265-1269	13.6	7
84	An update on emerging drugs for fibromyalgia treatment. <i>Expert Opinion on Emerging Drugs</i> , <b>2017</b> , 22, 357-367	3.7	10
83	Acute and chronic pain in orthopaedic and rheumatologic diseases: mechanisms and characteristics. <i>Clinical and Experimental Rheumatology</i> , <b>2017</b> , 35 Suppl 105, 127-131	2.2	2
82	Drug survival of adalimumab in patients with rheumatoid arthritis over 10 years in the real-world settings: high rate remission together with normal function ability. <i>Clinical Rheumatology</i> , <b>2016</b> , 35, 2649-2656 <sup>14</sup>	3.9	14
81	Novel pharmaceutical options for treating fibromyalgia. <i>Expert Review of Clinical Pharmacology</i> , <b>2016</b> , 9, 559-565	3.8	5
80	Low Risk of Hepatitis B Virus Reactivation in HBsAg-negative/Anti-HBc-positive Carriers Receiving Rituximab for Rheumatoid Arthritis: A Retrospective Multicenter Italian Study. <i>Journal of Rheumatology</i> , <b>2016</b> , 43, 869-74	4.1	37
79	Identifying the symptom and functional domains in patients with fibromyalgia: results of a cross-sectional Internet-based survey in Italy. <i>Journal of Pain Research</i> , <b>2016</b> , 9, 279-86	2.9	18

78	Correlations between immunogenicity, drug levels, and disease activity in an Italian cohort of rheumatoid arthritis patients treated with tocilizumab. <i>Biologics: Targets and Therapy</i> , <b>2016</b> , 10, 53-8	4.4	11
77	How to measure chronic pain: New concepts. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2015</b> , 29, 164-86	5.3	14
76	Building bridges between doctors and patients: the design and pilot evaluation of a training session in argumentation for chronic pain experts. <i>BMC Medical Education</i> , <b>2015</b> , 15, 89	3.3	7
75	Investigating the potential side effects of anti-TNF therapy for rheumatoid arthritis: cause for concern?. <i>Immunotherapy</i> , <b>2015</b> , 7, 353-61	3.8	21
74	Role of Agents other than Tumor Necrosis Factor Blockers in the Treatment of Psoriatic Arthritis. <i>Journal of rheumatology Supplement, The</i> , <b>2015</b> , 93, 79-81		8
73	The prevalence of fibromyalgia in the general population: a comparison of the American College of Rheumatology 1990, 2010, and modified 2010 classification criteria. <i>Arthritis and Rheumatology</i> , <b>2015</b> , 67, 568-75	9.5	232
72	Measuring psoriatic disease in clinical practice. An expert opinion position paper. <i>Autoimmunity Reviews</i> , <b>2015</b> , 14, 864-74	13.6	22
71	Pain in systemic inflammatory rheumatic diseases. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2015</b> , 29, 42-52	5.3	21
70	Serological epitope profile of anti-Ro52-positive patients with systemic autoimmune rheumatic diseases. <i>Arthritis Research and Therapy</i> , <b>2015</b> , 17, 365	5.7	10
69	A possible link between ankylosing spondylitis and periodontitis: a systematic review and meta-analysis. <i>Rheumatology</i> , <b>2015</b> , 54, 500-10	3.9	8
68	Helicobacter pylori Infection and Gastric Autoimmunity <b>2015</b> , 495-503		
67	Rheumatic manifestations in inflammatory bowel disease. <i>Autoimmunity Reviews</i> , <b>2014</b> , 13, 20-3	13.6	48
66	Fibromyalgia in patients with axial spondyloarthritis: epidemiological profile and effect on measures of disease activity. <i>Rheumatology International</i> , <b>2014</b> , 34, 1103-10	3.6	72
65	Autoimmunity and the Newer Biopharmaceuticals <b>2014</b> , 795-802		1
64	Prédicteurs de la réponse aux traitements anti-TNF chez les patients ayant une polyarthrite rhumatoïde avec des scores DAS28 modérés ou élevés. <i>Revue Du Rhumatisme (Edition Française)</i> , <b>2014</b> , 81, 54-57	0.1	
63	Predictors of response to anti-TNF therapy in RA patients with moderate or high DAS28'scores. <i>Joint Bone Spine</i> , <b>2014</b> , 81, 37-40	2.9	19
62	Doctors' insights into the patient perspective: a qualitative study in the field of chronic pain. <i>BioMed Research International</i> , <b>2014</b> , 2014, 514230	3	15
61	Effects of anti-TNF alpha drugs on disability in patients with rheumatoid arthritis: long-term real-life data from the Lorhen Registry. <i>BioMed Research International</i> , <b>2014</b> , 2014, 416892	3	7

60	New biological treatments for psoriatic arthritis. <i>Israel Medical Association Journal</i> , <b>2014</b> , 16, 643-5	0.9	4
59	Different effects of biological drugs in rheumatoid arthritis. <i>Autoimmunity Reviews</i> , <b>2013</b> , 12, 575-9	13.6	66
58	Long-term safety of abatacept in patients with rheumatoid arthritis. <i>Autoimmunity Reviews</i> , <b>2013</b> , 12, 1115-7	13.6	28
57	Silent cardiovascular involvement in patients with diffuse systemic sclerosis: a controlled cross-sectional study. <i>Arthritis Care and Research</i> , <b>2013</b> , 65, 274-80	4.7	34
56	Immunogenicity and autoimmunity during anti-TNF therapy. <i>Autoimmunity Reviews</i> , <b>2013</b> , 12, 703-8	13.6	145
55	Lung involvement and drug-induced lung disease in patients with rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , <b>2013</b> , 9, 649-57	5.1	29
54	Factors correlated with improvement of endothelial dysfunction during rituximab therapy in patients with rheumatoid arthritis. <i>Biologics: Targets and Therapy</i> , <b>2013</b> , 7, 69-75	4.4	24
53	Efficacy of ketoprofen vs. ibuprofen and diclofenac: a systematic review of the literature and meta-analysis. <i>Clinical and Experimental Rheumatology</i> , <b>2013</b> , 31, 731-8	2.2	13
52	Is fibromyalgia a discrete entity?. <i>Autoimmunity Reviews</i> , <b>2012</b> , 11, 585-8	13.6	27
51	Early treatment in early undifferentiated arthritis. <i>Autoimmunity Reviews</i> , <b>2012</b> , 11, 589-92	13.6	24
50	Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry. <i>Autoimmunity Reviews</i> , <b>2012</b> , 12, 225-9	13.6	125
49	Identification of the clinical features distinguishing psoriatic arthritis and fibromyalgia. <i>Journal of Rheumatology</i> , <b>2012</b> , 39, 849-55	4.1	75
48	The effect of tumor necrosis factor- $\alpha$ antagonists on arterial stiffness in rheumatoid arthritis: a literature review. <i>Seminars in Arthritis and Rheumatism</i> , <b>2012</b> , 42, 1-8	5.3	36
47	Twelve years' experience with etanercept in the treatment of rheumatoid arthritis: how it has changed clinical practice. <i>Expert Review of Clinical Immunology</i> , <b>2012</b> , 8, 213-22	5.1	8
46	CC chemokine receptor 5 polymorphism in Italian patients with Behcet's disease. <i>Rheumatology</i> , <b>2012</b> , 51, 2141-5	3.9	10
45	Longterm retention of tumor necrosis factor- $\alpha$ inhibitor therapy in a large italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictors. <i>Journal of Rheumatology</i> , <b>2012</b> , 39, 1179-84	4.1	80
44	Determinants of Risk Infection During Therapy with Anti TNF-Alpha Blocking Agents in Rheumatoid Arthritis. <i>Open Rheumatology Journal</i> , <b>2012</b> , 6, 33-7	0.2	7
43	Echocardiographic approach in systemic autoimmune diseases. <i>Journal of Cardiovascular Echography</i> , <b>2011</b> , 21, 152-156	0.6	

42	Clinical and laboratory aspects of Ro/SSA-52 autoantibodies. <i>Autoimmunity Reviews</i> , <b>2011</b> , 10, 150-4	13.6	75
41	Switching rheumatoid arthritis treatments: an update. <i>Autoimmunity Reviews</i> , <b>2011</b> , 10, 397-403	13.6	28
40	Chronic widespread pain in the spectrum of rheumatological diseases. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2011</b> , 25, 165-71	5.3	69
39	Clinimetric evaluations of patients with chronic widespread pain. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2011</b> , 25, 249-70	5.3	16
38	Multidisciplinary approach to fibromyalgia: what is the teaching?. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2011</b> , 25, 311-9	5.3	32
37	Coronary flow reserve and asymmetric dimethylarginine levels: new measurements for identifying subclinical atherosclerosis in patients with psoriatic arthritis. <i>Journal of Rheumatology</i> , <b>2011</b> , 38, 1661-4	4.1	36
36	Etanercept plus ciclosporin versus etanercept plus methotrexate for maintaining clinical control over psoriatic arthritis: a randomised pilot study. <i>Annals of the Rheumatic Diseases</i> , <b>2011</b> , 70, 712-4	2.4	25
35	PLA1/A2 polymorphism of the platelet glycoprotein receptors IIIA in Behçet's disease. <i>Clinical and Experimental Rheumatology</i> , <b>2011</b> , 29, S38-43	2.2	
34	Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology I. Efficacy. <i>Clinical and Experimental Rheumatology</i> , <b>2011</b> , 29, S7-14	2.2	23
33	Efficacy and safety of anti-tumour necrosis factor in elderly patients with rheumatoid arthritis: an observational study. <i>Clinical Reviews in Allergy and Immunology</i> , <b>2010</b> , 38, 90-6	12.3	52
32	The heart in rheumatoid arthritis. <i>Autoimmunity Reviews</i> , <b>2010</b> , 9, 414-8	13.6	28
31	Predictive factors of response to rituximab therapy in rheumatoid arthritis: What do we know today?. <i>Autoimmunity Reviews</i> , <b>2010</b> , 9, 801-3	13.6	36
30	The effect of pharmacological therapy on the cardiovascular system of patients with systemic rheumatic diseases. <i>Autoimmunity Reviews</i> , <b>2010</b> , 9, 835-9	13.6	62
29	Usefulness of cardiovascular biomarkers and cardiac imaging in systemic rheumatic diseases. <i>Autoimmunity Reviews</i> , <b>2010</b> , 9, 845-8	13.6	12
28	Cardiac involvement in systemic rheumatic diseases: An update. <i>Autoimmunity Reviews</i> , <b>2010</b> , 9, 849-52	13.6	58
27	Extraspinal manifestations of diffuse idiopathic skeletal hyperostosis. <i>Rheumatology</i> , <b>2009</b> , 48, 1478-81	3.9	109
26	TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. <i>Annals of the New York Academy of Sciences</i> , <b>2009</b> , 1173, 837-46	6.5	110
25	Cardiovascular involvement in systemic autoimmune diseases. <i>Autoimmunity Reviews</i> , <b>2009</b> , 8, 281-6	13.6	90

24	Serious infections during anti-TNFalpha treatment in rheumatoid arthritis patients. <i>Autoimmunity Reviews</i> , <b>2009</b> , 8, 266-73	13.6	134
23	Treatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisal. <i>Autoimmunity Reviews</i> , <b>2009</b> , 8, 274-80	13.6	89
22	Predicting response to anti-TNF treatment in rheumatoid arthritis patients. <i>Autoimmunity Reviews</i> , <b>2009</b> , 8, 431-7	13.6	47
21	Non-invasive assessment of coronary flow reserve and ADMA levels: a case-control study of early rheumatoid arthritis patients. <i>Rheumatology</i> , <b>2009</b> , 48, 834-9	3.9	80
20	Development and validation of the self-administered Fibromyalgia Assessment Status: a disease-specific composite measure for evaluating treatment effect. <i>Arthritis Research and Therapy</i> , <b>2009</b> , 11, R125	5.7	33
19	Resistant cases of psoriatic arthritis: how to manage them. <i>Journal of rheumatology Supplement, The</i> , <b>2009</b> , 83, 73-5		4
18	Combined therapeutic approach: inflammatory bowel diseases and peripheral or axial arthritis. <i>World Journal of Gastroenterology</i> , <b>2009</b> , 15, 2469-71	5.6	18
17	Anti-cytokine antibodies for rheumatic diseases. <i>Current Opinion in Investigational Drugs</i> , <b>2009</b> , 10, 1204-11		21
16	Etiology of fibromyalgia: the possible role of infection and vaccination. <i>Autoimmunity Reviews</i> , <b>2008</b> , 8, 41-3	13.6	88
15	Anti-cyclic citrullinated peptide antibodies in primary Sjögren syndrome may be associated with non-erosive synovitis. <i>Arthritis Research and Therapy</i> , <b>2008</b> , 10, R51	5.7	49
14	Organ-specific autoantibodies in patients with rheumatoid arthritis treated with adalimumab: a prospective long-term follow-up. <i>Autoimmunity</i> , <b>2008</b> , 41, 87-91	3	8
13	Autoantibody production in patients treated with anti-TNF-alpha. <i>Expert Review of Clinical Immunology</i> , <b>2008</b> , 4, 275-80	5.1	34
12	What is the role of rituximab in the treatment of rheumatoid arthritis?. <i>Autoimmunity Reviews</i> , <b>2007</b> , 6, 553-8	13.6	23
11	Potential target of infliximab in autoimmune and inflammatory diseases. <i>Autoimmunity Reviews</i> , <b>2007</b> , 6, 529-36	13.6	38
10	Preclinical impairment of coronary flow reserve in patients with rheumatoid arthritis. <i>Annals of the New York Academy of Sciences</i> , <b>2007</b> , 1108, 392-7	6.5	13
9	Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study. <i>Arthritis Research and Therapy</i> , <b>2006</b> , 8, R3	5.7	88
8	Long-term prognosis and causes of death in systemic lupus erythematosus. <i>American Journal of Medicine</i> , <b>2006</b> , 119, 700-6	2.4	215
7	Autoimmunity and anti-TNF-alpha agents. <i>Annals of the New York Academy of Sciences</i> , <b>2005</b> , 1051, 559-69		135

6	The role of echocardiographic techniques in connective tissue diseases. <i>Autoimmunity Reviews</i> , <b>2005</b> , 4, 171-7	13.6	11
5	TNF-alpha, rheumatoid arthritis, and heart failure: a rheumatological dilemma. <i>Autoimmunity Reviews</i> , <b>2005</b> , 4, 153-61	13.6	99
4	Five-year follow-up by transesophageal echocardiographic studies in primary antiphospholipid syndrome. <i>American Journal of Cardiology</i> , <b>2005</b> , 96, 574-9	3	54
3	Successful treatment of pure red cell aplasia in systemic lupus erythematosus with cyclosporin A. <i>Clinical and Experimental Rheumatology</i> , <b>2003</b> , 21, 759-62	2.2	11
2	Correlation of the score for subjective pain with physical disability, clinical and radiographic scores in recent onset rheumatoid arthritis. <i>BMC Musculoskeletal Disorders</i> , <b>2002</b> , 3, 18	2.8	32
1	Induction of CD69 activation molecule on human neutrophils by GM-CSF, IFN-gamma, and IFN-alpha. <i>Cellular Immunology</i> , <b>2002</b> , 220, 20-9	4.4	38